Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Receivables - Net data on file, last reported at $38000.0 in Q2 2023.

• For the quarter ending Q2 2023, Receivables - Net fell 93.01% year-over-year to $38000.0; the trailing twelve-month figure through Jun 2023 stood at $38000.0 (down 93.01% YoY), and the FY2021 full-year result was $1.1 million, down 51.31% from the prior year.
• Receivables - Net for Q2 2023 stood at $38000.0, down from $544000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $5.0 million in Q3 2019 and bottomed at $38000.0 in Q2 2023.
• The 5-year median for Receivables - Net is $2.0 million (2020), against an average of $2.1 million.
• The widest annual swing landed in 2020, when Receivables - Net surged 117.34%; it then tumbled 93.01% in 2023.
• A 5-year view of Receivables - Net shows it stood at $1.0 million in 2019, then jumped by 117.34% to $2.2 million in 2020, then slumped by 51.31% to $1.1 million in 2021, then plunged by 48.68% to $544000.0 in 2022, then sank by 93.01% to $38000.0 in 2023.
• The last three Receivables - Net figures came in at $38000.0 (Q2 2023), $544000.0 (Q2 2022), and $938000.0 (Q1 2022), per Business Quant data.

Peer Comparison